
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Precision for Medicine has announced the strategic acquisition of SolveBio by QuartzBio. SolveBio's technologies and enterprise data management platform has integrated into QuartzBio's suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.
Read more about the acquisition






